BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC) Files An 8-K Other EventsItem 8.01 Other Events.
On July 3, 2018, Mr. Thomas L. Wegman, President and member of the board of directors of BioSpecifics Technologies Corp. (the “Company”), issued a letter to the Company’s employees, partners and shareholders informing them of his diagnosis with and treatment of a medical condition. A copy of his letter is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| Exhibit | Description |
| No. | |
| 99.1 | Message from Mr. Thomas L. Wegman. |
2
BIOSPECIFICS TECHNOLOGIES CORP ExhibitEX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 BioSpecifics Technologies Corp….To view the full exhibit click here
About BIOSPECIFICS TECHNOLOGIES CORP. (NASDAQ:BSTC)
BioSpecifics Technologies Corp. (BioSpecifics) is a biopharmaceutical company. The Company is engaged in the development of an injectable collagenase clostridium histolyticum (CCH) for multiple indications. The Company has a development and license agreement with Endo International plc (Endo) for injectable collagenases for marketed indications and indications in development. CCH is marketed as XIAFLEX and as XIAPEX in Europe. Its injectable collagenases are marketed for indications, such as Dupuytren’s contracture and Peyronie’s disease. BioSpecifics is conducting development work with respect to human lipoma and uterine fibroids. XIAFLEX and XIAPEX are approved in the United States, the European Union, Switzerland, Canada, Australia and Japan for the treatment of Dupuytren’s contracture. Endo manages the research and development of XIAFLEX for their licensed indications, including frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis and uterine fibroids.